S –°–ø—ñ–Ω–∞–ª—å–Ω–∞ –º'—è–∑–æ–≤–∞ –∞—Ç—Ä–æ—Ñ—ñ—è ( –°–ú–ê ) , —á–∞—Å—Ç–∏–Ω–∞ –¥—Ä—É–≥–∞ : –ª—ñ–∫—É–≤–∞–Ω–Ω—è .
A -1 -1|||noop|||-NONE-|||-NONE-|||-NONE-|||1

S –î–ª—è –∫—Ä–∞—â–æ–≥–æ —Ä–æ–∑—É–º—ñ–Ω–Ω—è —Ä–µ–∫–æ–º–µ–Ω–¥—É—é –ø–æ–ø–µ—Ä–µ–¥–Ω—ñ–π –¥–æ–ø–∏—Å –ø—Ä–æ –°–ú–ê : –ª—ñ–Ω–∫ .
A -1 -1|||noop|||-NONE-|||-NONE-|||-NONE-|||1

S –†–∞–Ω—ñ—à–µ –ø—Ä–∏ 5q —Ñ–æ—Ä–º—ñ –°–ú–ê , —è–∫–∞ –ø–æ–≤'—è–∑–∞–Ω–∞ —ñ–∑ –∑–Ω–∏–∂–µ–Ω–Ω—è–º —á–∏ –≤—Ç—Ä–∞—Ç–æ—é –µ–∫—Å–ø—Ä–µ—Å—ñ—ó SMN1 , —ñ—Å–Ω—É–≤–∞–ª–æ –ª–∏—à–µ —Å–∏–º–ø—Ç–æ–º–∞—Ç–∏—á–Ω–µ –ª—ñ–∫—É–≤–∞–Ω–Ω—è , –ø—Ä–æ—Ç–µ –≤ –ø–æ–ø–µ—Ä–µ–¥–Ω—ñ —Ä–æ–∫–∏ –±—É–ª–∏ c—Ö–≤–∞–ª–µ–Ω—ñ –¥–≤–∞ –ø—Ä–µ–ø–∞—Ä–∞—Ç–∏ , —â–æ –∑–¥–∞—Ç–Ω—ñ –º–æ–¥–∏—Ñ—ñ–∫—É–≤–∞—Ç–∏ –ø–µ—Ä–µ–±—ñ–≥ —Ö–≤–æ—Ä–æ–±–∏ .
A -1 -1|||noop|||-NONE-|||-NONE-|||-NONE-|||1

S üíâ Nusinersen ( –∫–æ–º–µ—Ä—Ü—ñ–π–Ω–∞ –Ω–∞–∑–≤–∞ : Spinraza ) ‚Äî —Ü–µ –ø–µ—Ä—à–∏–π –ø—Ä–µ–ø–∞—Ä–∞—Ç –¥–ª—è –ª—ñ–∫—É–≤–∞–Ω–Ω—è –°–ú–ê , —è–∫–∏–π –æ—Ç—Ä–∏–º–∞–≤ –∞–≤—Ç–æ—Ä–∏–∑–∞—Ü—ñ—é FDA ( 2016 —Ä—ñ–∫ ) —Ç–∞ EMA ( 2017 —Ä—ñ–∫ ) .
A -1 -1|||noop|||-NONE-|||-NONE-|||-NONE-|||1

S –†–∞–Ω—ñ—à–µ –±—É–≤ –≤—ñ–¥–∫—Ä–∏—Ç–∏–π intronic splicing silencer N1 ( ISS - N1 ) , —Ñ–∞–∫—Ç–æ—Ä , —è–∫–∏–π –ø—Ä–∏–∑–≤–æ–¥–∏—Ç—å –¥–æ —Å–ø–ª–∞–π—Å–∏–Ω–≥—É —Å—å–æ–º–æ–≥–æ –µ–∫–∑–æ–Ω—É –ø—Ä–µ-–º–†–ù–ö –≥–µ–Ω—É SMN2 , —á–µ—Ä–µ–∑ —â–æ —Ü–µ–π –≥–µ–Ω —Å–∞–º –Ω–µ –º–æ–∂–µ –ø—Ä–æ–¥—É–∫—É–≤–∞—Ç–∏ –¥–æ—Å—Ç–∞—Ç–Ω—é –∫—ñ–ª—å–∫—ñ—Å—Ç—å —Ñ—É–Ω–∫—Ü—ñ–æ–Ω–∞–ª—å–Ω–æ–≥–æ –±—ñ–ª–∫–∞ SMN .
A 33 35|||G/Case|||–¥–æ—Å—Ç–∞—Ç–Ω—å–æ—ó –∫—ñ–ª—å–∫–æ—Å—Ç—ñ|||REQUIRED|||-NONE-|||1

S Nusinersen —î –∞–Ω—Ç–∏—Å–µ–Ω—Å –æ–ª—ñ–≥–æ–Ω—É–∫–ª–µ–æ—Ç–∏–¥–æ–º –¥–æ ISS - N1 , —á–µ—Ä–µ–∑ –π–æ–≥–æ –±–ª–æ–∫—É–≤–∞–Ω–Ω—è —Å—å–æ–º–∏–π –µ–∫–∑–æ–Ω –∑–∞–ª–∏—à–∞—î—Ç—å—Å—è —É —Å–∫–ª–∞–¥—ñ –º–†–ù–ö , —è–∫–∞ –ø–æ—Ç—ñ–º —Ç—Ä–∞–Ω—Å–ª—é—î—Ç—å—Å—è —É –ø–æ–≤–Ω–æ—Ü—ñ–Ω–Ω–∏–π SMN .
A -1 -1|||noop|||-NONE-|||-NONE-|||-NONE-|||1

S üíâ Onasemnogene abeparvovec ( –∫–æ–º–µ—Ä—Ü—ñ–π–Ω–∞ –Ω–∞–∑–≤–∞ : Zolgensma ) ‚Äî —Ü–µ –≥–µ–Ω–Ω–∞ —Ç–µ—Ä–∞–ø—ñ—è , –∞–≤—Ç–æ—Ä–∏–∑–æ–≤–∞–Ω–∞ FDA ( 2019 —Ä—ñ–∫ ) —Ç–∞ —è–∫–∞ —Ä–æ–∑–≥–ª—è–¥–∞—î—Ç—å—Å—è EMA ( –ª—ñ–Ω–∫ ) .
A -1 -1|||noop|||-NONE-|||-NONE-|||-NONE-|||1

S –ü—Ä–µ–ø–∞—Ä–∞—Ç —î –≥–µ–Ω–µ—Ç–∏—á–Ω–∏–º –≤–µ–∫—Ç–æ—Ä–æ–º , —â–æ –±–∞–∑—É—î—Ç—å—Å—è –Ω–∞ –∞–¥–µ–Ω–æ - –∞—Å–æ—Ü—ñ–π–æ–≤–∞–Ω–æ–º—É –≤—ñ—Ä—É—Å—ñ , —ñ –¥–æ—Å—Ç–∞–≤–ª—è—î —É –∫–ª—ñ—Ç–∏–Ω–∏ –∫–æ–ø—ñ—é –≥–µ–Ω–∞ , –∑–¥–∞—Ç–Ω—É –ø—Ä–æ–¥—É–∫—É–≤–∞—Ç–∏ —Ñ—É–Ω–∫—Ü—ñ–æ–Ω–∞–ª—å–Ω–∏–π SMN .
A 8 11|||Spelling|||–∞–¥–µ–Ω–æ–∞—Å–æ—Ü—ñ–π–æ–≤–∞–Ω–æ–º—É|||REQUIRED|||-NONE-|||1

S –¶–µ–π –≤–µ–∫—Ç–æ—Ä –Ω–µ —î –ø–∞—Ç–æ–≥–µ–Ω–Ω–∏–º –¥–ª—è –ª—é–¥–∏–Ω–∏ —Ç–∞ –º–∞—î —Ç—Ä–æ–ø—ñ–∑–º –¥–æ –Ω–µ–π—Ä–æ–Ω—ñ–≤ .
A -1 -1|||noop|||-NONE-|||-NONE-|||-NONE-|||1

S –ß–∏ —î –ª—ñ–∫—É–≤–∞–Ω–Ω—è –°–ú–ê –∑–∞–∫—Ä–∏—Ç–∏–º –ø–∏—Ç–∞–Ω–Ω—è–º ?
A -1 -1|||noop|||-NONE-|||-NONE-|||-NONE-|||1

S –ù–∞ –∂–∞–ª—å , –Ω—ñ .
A -1 -1|||noop|||-NONE-|||-NONE-|||-NONE-|||1

S –ï—Ñ–µ–∫—Ç–∏–≤–Ω—ñ—Å—Ç—å –ø—Ä–µ–ø–∞—Ä–∞—Ç—ñ–≤ –Ω–µ —î —Å—Ç–æ–≤—ñ–¥—Å–æ—Ç–∫–æ–≤–æ—é , –Ω–∞–π–±—ñ–ª—å—à –µ—Ñ–µ–∫—Ç–∏–≤–Ω—ñ –≤–æ–Ω–∏ –ø—Ä–∏ —Ä–∞–Ω–Ω—å–æ–º—É –ø—Ä–∏–∑–Ω–∞—á–µ–Ω–Ω—ñ .
A 6 8|||G/Comparison|||–Ω–∞–π–µ—Ñ–µ–∫—Ç–∏–≤–Ω—ñ—à—ñ|||REQUIRED|||-NONE-|||1

S –¥–ª—è –¥—ñ—Ç–µ–π —Å—Ç–∞—Ä—à–µ 12 —Ä–æ–∫—ñ–≤ –ø—Ä–∏–∑–Ω–∞—á–µ–Ω–Ω—è Nusinersen –º–æ–∂–µ –º–∞—Ç–∏ –ø–µ—Ä–µ–≤–∞–≥–∏ , –µ—Ñ–µ–∫—Ç–∏–≤–Ω—ñ—Å—Ç—å —ñ–Ω—à–æ–≥–æ –ø—Ä–µ–ø–∞—Ä–∞—Ç—É –¥–ª—è –¥—ñ—Ç–µ–π —Å—Ç–∞—Ä—à–µ –¥–≤–æ—Ö —Ä–æ–∫—ñ–≤ –Ω–µ–≤—ñ–¥–æ–º–∞ .
A 0 1|||Spelling|||–î–ª—è|||REQUIRED|||-NONE-|||1
A 2 3|||G/Prep|||–≤—ñ–¥|||REQUIRED|||-NONE-|||1
A 16 17|||G/Prep|||–≤—ñ–¥|||REQUIRED|||-NONE-|||1

S –ü–µ—Ä—à–∏–π –ø—Ä–µ–ø–∞—Ä–∞—Ç –≤–∏–º–∞–≥–∞—î –≤–≤–µ–¥–µ–Ω–Ω—è —Ä–∞–∑ –Ω–∞ —á–æ—Ç–∏—Ä–∏ –º—ñ—Å—è—Ü—ñ —ñ–Ω—Ç—Ä–∞—Ç–µ–∫–∞–ª—å–Ω–æ –ø—Ä–æ—Ç—è–≥–æ–º —É—Å—å–æ–≥–æ –∂–∏—Ç—Ç—è , –æ–±–∏–¥–≤–∞ –ø—Ä–µ–ø–∞—Ä–∞—Ç—ñ –º–∞—é—Ç—å —Å–µ—Ä–π–æ–∑–Ω—ñ –ø–æ–±—ñ—á–Ω—ñ –µ—Ñ–µ–∫—Ç–∏ , –∑–æ–∫—Ä–µ–º–∞ —É spinraza - –Ω–µ—Ñ—Ä–æ—Ç–æ–∫—Å–∏—á–Ω—ñ—Å—Ç—å ( –ª—ñ–Ω–∫ ) , —É zolgensma - –≥–æ—Å—Ç—Ä–µ –≤—Ä–∞–∂–µ–Ω–Ω—è –ø–µ—á—ñ–Ω–∫–∏ ( –ª—ñ–Ω–∫ ) .
A 23 24|||Punctuation|||‚Äî|||REQUIRED|||-NONE-|||1
A 31 32|||Punctuation|||‚Äî|||REQUIRED|||-NONE-|||1

S –¶—ñ–Ω–∞ spinraza –∑–∞ –æ–¥–Ω—É –¥–æ–∑—É - –ø—Ä–∏–±–ª–∏–∑–Ω–æ $ 125,000 , —Ü—ñ–Ω–∞ zolgensma –∑–∞ —î–¥–∏–Ω—É –Ω–µ–æ–±—Ö—ñ–¥–Ω—É –¥–æ–∑—É - –±—ñ–ª—å—à –∑–∞ $ 2,000,000 .
A 5 6|||Punctuation|||‚Äî|||REQUIRED|||-NONE-|||1
A 16 17|||Punctuation|||‚Äî|||REQUIRED|||-NONE-|||1

S –ü—Ä–æ—Ç–µ , —Ü–µ —î–¥–∏–Ω–µ –¥–æ—Å—Ç—É–ø–Ω–µ –ª—ñ–∫—É–≤–∞–Ω–Ω—è , —è–∫–µ –º–æ–∂–µ –∑–∞–ø–æ–±—ñ–≥—Ç–∏ —Ä–æ–∑–≤–∏—Ç–∫—É —Å–∏–º–ø—Ç–æ–º—ñ–≤ —Ö–≤–æ—Ä–æ–±–∏ .
A 1 2|||Punctuation|||-NONE-|||REQUIRED|||-NONE-|||1

S üñ• –ó–≥—ñ–¥–Ω–æ –∑ clinicaltrials .gov , –Ω–∞—Ä–∞–∑—ñ –∞–∫—Ç–∏–≤–Ω—ñ 11 –¥–æ—Å–ª—ñ–¥–∂–µ–Ω—å –≤ —Ñ–∞–∑—ñ –Ü —Ç–∞ –Ü–Ü , —Ç–æ–º—É , –º–æ–∂–ª–∏–≤–æ , —Ç–µ—Ä–∞–ø–µ–≤—Ç–∏—á–Ω–∏—Ö –∑–∞—Å–æ–±—ñ–≤ —É –Ω–∞–π–±–ª–∏–∂—á—ñ —Ä–æ–∫–∏ —Å—Ç–∞–Ω–µ –±—ñ–ª—å—à–µ .
A 10 11|||Spelling|||—É|||REQUIRED|||-NONE-|||1

S –î–æ —Ç–æ–≥–æ –∂ , —Ü—ñ–Ω–∞ –Ω–∞ –Ω–∞—è–≤–Ω—É —Ç–µ—Ä–∞–ø—ñ—é , —Å–∫–æ—Ä—ñ—à –∑–∞ –≤—Å–µ , –∑–Ω–∏–∑–∏—Ç—å—Å—è –∑ —á–∞—Å–æ–º .
A -1 -1|||noop|||-NONE-|||-NONE-|||-NONE-|||1

S –ü—Ä–æ—Ç–µ , –º–æ–∂–ª–∏–≤–æ , —Ü–µ —Å—Ç–∞–Ω–µ—Ç—å—Å—è –ª–∏—à–µ –ø—ñ—Å–ª—è –∑–∞–≤–µ—Ä—à–µ–Ω–Ω—è —Ç–µ—Ä–º—ñ–Ω—É –¥—ñ—ó –ø–∞—Ç–µ–Ω—Ç—É .
A -1 -1|||noop|||-NONE-|||-NONE-|||-NONE-|||1

S –î–∂–µ—Ä–µ–ª–∞ :
A -1 -1|||noop|||-NONE-|||-NONE-|||-NONE-|||1

S 1 . Olaf A Bodamer Spinal muscular atrophy .
A -1 -1|||noop|||-NONE-|||-NONE-|||-NONE-|||1

S UpToDate 2019
A -1 -1|||noop|||-NONE-|||-NONE-|||-NONE-|||1

S http://bit.ly/2rX9Z0X
A -1 -1|||noop|||-NONE-|||-NONE-|||-NONE-|||1

S 2 . Eric W . Ottesen ISS - N1 makes the First FDA -approved Drug for Spinal Muscular Atrophy .
A -1 -1|||noop|||-NONE-|||-NONE-|||-NONE-|||1

S Transl Neurosci .
A -1 -1|||noop|||-NONE-|||-NONE-|||-NONE-|||1

S 2017 ; 8 : 1 ‚Äì 6
A -1 -1|||noop|||-NONE-|||-NONE-|||-NONE-|||1

S http://bit.ly/2PsQDtI
A -1 -1|||noop|||-NONE-|||-NONE-|||-NONE-|||1

S # –≥–µ–Ω–µ—Ç–∏—á–Ω—ñ_—Ö–≤–æ—Ä–æ–±–∏
A -1 -1|||noop|||-NONE-|||-NONE-|||-NONE-|||1

